Antibody-dependent cell-mediated cytotoxicity (ADCC), largely mediated by natural killer (NK) cells, is thought to play an important role in the efficacy of rituximab, an anti-CD20 monoclonal antibody (mAb) used to treat patients with B cell lymphomas. CD137 is a costimulatory molecule expressed on a variety of immune cells following activation, including NK cells. Here we show that an anti-CD137 agonistic mAb enhances the anti-lymphoma activity of rituximab by enhancing ADCC. Human NK cells upregulate CD137 after encountering rituximab-coated tumor B cells and subsequent stimulation of these NK cells with anti-CD137 mAb enhances rituximab-dependent cytotoxicity against the lymphoma cells. In a syngeneic murine lymphoma model and in a xenotransplanted human lymphoma model, sequential administration of anti-CD20 mAb followed by anti-CD137 mAb has potent anti-lymphoma activity in-vivo. These results support a novel, sequential antibody approach against B cell malignancies by targeting first the tumor and then the host immune system.
Introduction
Monoclonal antibodies have revolutionized the treatment of cancer. The first approved monoclonal antibody (mAb) for this purpose, rituximab, a murine-human chimeric IgG1 antibody against CD20, has become a standard treatment for patients with B cell lymphomas.
Despite tumor response rates to rituximab of up to 90% and decreased risk of death by as much as 36%, the majority of patients with advanced lymphoma still die of their disease, including 19 ,000 patients in the United States in 2009 alone [1] [2] [3] [4] . Enhancing the efficacy of rituximab represents an opportunity to improve patients' outcomes. Here, we have developed a strategy to enhance the anti-tumor activity of rituximab by augmenting antibody-induced cell killing.
Several mechanisms of rituximab's anti-tumor action have been proposed including direct induction of apoptosis, complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity (ADCC), and possibly, induction of an adaptive immune response ("vaccinal" effect) 5 . Among these mechanisms, ADCC is believed to be of importance, particularly to the initial anti-tumor response. In-vitro studies have shown that rituximab can induce ADCC of human lymphoma cell lines 6 . In murine xenotransplant lymphoma models, a role for ADCC in rituximab's efficacy was confirmed in studies using FcR-γ chain-deficient mice 7 , as well as a neutralizing antibody against murine FcγR 8 . Further murine studies using CD20 mAbs have confirmed that monocyte-mediated ADCC is the primary, if not exclusive, mechanism through which normal and malignant B cells are depleted in-vivo [9] [10] [11] [12] [13] . Finally, clinical results have shown that patients harboring an FcγRIIIA polymorphism, with higher affinity for IgG1, have better responses to rituximab, further supporting the hypothesis that ADCC is an important in-vivo mechanism of rituximab action in patients with lymphoma 14, 15 . Natural killer (NK) cells are known to be important effector cells mediating ADCC. Binding of the NK cell Fc receptor (FcγRIII, CD16) to the constant region of an antibody induces NK cell activation. Upon activation, NK cells release cytotoxic granules promoting tumor cell killing, and upregulate expression of several activation markers including CD137 16 . In this study, we hypothesized that rituximabinduced ADCC could be specifically increased by using an anti-CD137 agonistic mAb to enhance NK cell function.
CD137 (4-1BB) is a surface glycoprotein that belongs to the tumor-necrosis factor receptor superfamily (TNFRSF) 17 . CD137 is an inducible costimulatory molecule expressed on a variety
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From of immune cells including activated CD4 and CD8 T cells, NK cells, monocytes, and dendritic cells 18, 19 . On T cells specifically, CD137 functions as a costimulatory receptor induced upon Tcell receptor (TCR) stimulation. In this context, ligation of CD137 leads to increased T-cell proliferation, cytokine production, functional maturation, and prolonged CD8 T-cell survival 18, 20 .
Consistent with the costimulatory function of CD137 on T cells, agonistic mAbs against this receptor have been shown to provoke powerful tumor-specific T-cell responses capable of eradicating tumor cells in a variety of murine tumor models including breast, sarcoma, mastocytoma, glioma, colon carcinoma, and myeloma [20] [21] [22] . Based on these preclinical results, an agonistic anti-CD137 mAb has now entered clinical trials for solid tumors. More recently, we have shown in a murine model that anti-CD137 agonistic mAb also had potent anti-lymphoma activity, requiring both CD8 T cells and NK cells 23 .
Despite extensive studies of its effect on T cells, the role of CD137 stimulation on the innate immune system is less well characterized. Recently, CD137 was shown to be upregulated on human NK cells following Fc-receptor triggering 16 . Further, CD137 stimulation has been shown to enhance NK cell function in mice 24, 25 , including a recent report demonstrating increased antitumor activity of NK cells following costimulation by gamma-delta T cells which is dependent on CD137 receptor/ligand interactions 26 . We hypothesized that as Fc-receptor triggering results in upregulation of CD137 expression on NK cells, stimulation via CD137 could enhance NK cell killing by ADCC and thereby augment the efficacy of rituximab. We first tested this hypothesis in-vitro using lymphoma cell lines and then confirmed our findings in-vivo in both a syngeneic, immunocompetent mouse model and a human xenotransplant model of lymphoma. Finally, we found that human NK cells upregulated their expression of CD137 when exposed to rituximabcoated, autologous lymphoma cells.
Material and Methods

Cell lines and mice
Human CD20-positive B cell lines including Raji and Ramos and a CD20-negative B cell line, 
Therapeutic antibodies
Anti-mouse CD137 (4-1BB) mAb (Rat IgG2a, clone 2A 28 ), with t 1/2 of 7 days, was produced from ascites in SCID mice as previously described 23, 29 . Sterile mouse anti-mouse CD20 mAb (MB20-11, Mouse IgG2c) was produced in-vitro 12 . IgG from rat serum was used as control antibody (Sigma-Aldrich). Human anti-human CD137 mAb (BMS-663513, human IgG4, which does not block the CD137 ligand) was provided by Bristol-Meyer Squibb. Rituximab (murine-human chimeric anti-CD20 IgG1) and trastuzumab (humanized anti-human epidermal growth factor receptor-2 IgG1) were obtained from Genentech.
CD137 expression on NK cells from patient samples and healthy individuals
Peripheral blood mononuclear cells (PBMCs) were isolated from patients with follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B cell lymphoma (DLBCL), and CD20-positive acute lymphoblastic leukemia (ALL), as well as healthy individuals by density gradient separation were incubated in-vitro with either no antibody, trastuzumab (10 µg/mL), or rituximab (10 µg/mL) for 24 hours prior to staining with mAbs and subsequent analysis by flow cytometry for CD137 expression. PBMCs isolated from healthy individuals or purified NK cells isolated by negative magnetic cell sorting using NK cell isolation beads (Miltenyi Biotec) according to manufacturer's instructions were cultured in complete media for 24 hours with a B cell line in the presence or absence of rituximab (10 µg/mL) or trastuzumab (10 µg/mL). Assessment of CD137 expression on NK cells from healthy individuals was performed three times and in triplicate.
In-vitro NK functional assays
To evaluate NK cell degranulation, CD107a mobilization was assayed 30 . Purified NK cells isolated by negative magnetic cell sorting using NK cell isolation beads (Miltenyi Biotec) were cultured alone, with lymphoma cell lines (Raji, Ramos, and DHL-4) at a ratio of 1:1, rituximab (10 µg/mL), and/or with anti-CD137 agonisitic mAb (10 µg/mL) for 24 hours with Golgi-stop (BD Biosciences) to prevent degradation of re-internalized CD107a proteins. Following 24 hours, cells were washed three times and mAb staining was carried out for analysis by flow cytometry.
Murine NK cells purified by negative magnetic cell sorting (Miltenyi Biotec) were evaluated for CD137 expression after culture with murine anti-murine anti-CD20 mAb.
To evaluate NK cell cytotoxicity for lymphoma cell lines, chromium release was performed as follows 31 : Healthy PBMCs were cultured for 24 hours together with rituximab (10 µg/mL) and irradiated (5,000 rads) lymphoma tumor cells (Raji, Ramos, or DHL-4) at a ratio of 1:1. After 24 hours, NK cells were isolated from these cultures by negative magnetic cell sorting using NK anti-CD137 mAb (BMS-663513, 10 µg/mL) alone, rituximab (10 µg/mL) alone, or rituximab plus anti-CD137 mAbs (both at 10 µg/mL).
Cells were cultured for interferon-γ assessment under similar conditions detailed above for assessment of cytotoxicity. Supernatant was analyzed for interferon-γ by ELISA method (Human interferon-γ BD OptEIA ELISA Set and BD OptEIA Reagent Set B, BD Pharmingen).
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Tumor transplantation and antibody therapy
BL3750 lymphoma cells were implanted into 8-10 week old female C57BL/6 mice at a dose of 5x10 6 cells in 50 μ L of PBS by the subcutaneous (s.c.) route on the abdomen. Monoclonal antibodies were administered by intra-peritoneal (i.p.) injections. Anti-CD20 mAb was given i.p.
on day 3 at 250 µg per injection and anti-CD137 mAb was given i.p. on day 4 at 150 µg per injection. Groups of 10 mice received either IgG alone on day 3, anti-CD20 mAb alone on day 3, anti-CD137 mAb alone on day 4, or both anti-CD20 mAb on day 3 and anti-CD137 mAb on day 4. To determine activity against well-established tumors, the identical treatment groups and sequence of antibodies was initiated on day 8 (IgG alone on day 8, anti-CD20 mAb alone on day 8, anti-CD137 mAb alone on day 9, or both anti-CD20 mAb on day 8 and anti-CD137 mAb on day 9). To optimize the sequence of antibody treatment, the anti-CD20 and anti-CD137 mAbs were given simultaneously on day 3 and directly compared to anti-CD20 mAb on day 3
and anti-CD137 mAb on day 4 in groups of 10 mice. Tumor growth was measured by caliper twice a week, and expressed as the product of length by width in square centimeters. Mice were sacrificed when tumor size reached 4 cm 2 or when tumor sites ulcerated. All in-vivo models were piloted with 5 mice per group and repeated with 10 mice per group.
Detection of CD137 expressing cells in-vivo
Blood was collected from the tail vein, anti-coagulated with 2 mM ethylenediaminetetraacetic (EDTA) acid in PBS, then diluted 1:1 with 2% Dextran T500 (Pharmacosmos) in PBS and incubated at 37°C for 45 minutes to precipitate red cells. Leukocyte-containing supernatant was removed and centrifuged, and the remaining red cells were lysed with ACK lysis buffer (Quality Biological). Subcutaneous tumors from 3 mice per treatment group were resected 7 days after inoculation and mechanically digested into a single cell suspension. Cells were stained with mAbs to evaluate CD137 expression on NK cells, macrophages, CD4 and CD8 T cells by flow cytometry.
Depletion of CD8 T cells, NK cells and macrophages
Anti-CD8 mAb, anti-Asialo GM1 mAb (Wako Chemicals) and liposomal clodronate (kindly provided by Weissman laboratory, Stanford) were used to deplete CD8 T cell, NK cell and 
Antibodies for flow cytometry
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The following mAbs to human antigens were used for staining of human PBMCs: CD16 FITC, CD107a FITC, CD137 ligand PE, CD56 PE, CD20 PE, CD62L PE-Cy5, CD3 PerCP, CD137 APC, CD69 APC-H7 (all from Becton Dickinson Biosciences (BD), CA). The following mAbs to mouse antigens were used: CD8 FITC (BD), CD4 FITC (BD), CD137 ligand PE (eBioscience), CD137 PE (eBioscience), CD3 PerCP (BD), NK1.1 APC (BD), and F4/80 APC (eBioscience).
Stained cells were collected on a FACSCalibur or a LSRII three-laser cytometer (BD) and data were analyzed using Cytobank (http://www.cytobank.org) 33 . 
Statistical analysis
Results
Rituximab induces CD137 upregulation on human NK cells in presence of CD20-positive tumor B cells
Human NK cells from healthy subjects were exposed to rituximab-coated malignant B cell lines.
These cells were incubated in-vitro either with rituximab or with trastuzumab (humanized IgG1 antibody against human epidermal growth factor receptor 2, not expressed by B cell lymphomas). After 24 hours, CD137 expression remained negative to minimal on NK cells in the absence of mAb or in the presence of trastuzumab. Exposure of NK cells to rituximab in the presence of a CD20-negative B cell line had no effect on CD137 expression by the NK cells. By contrast, rituximab together with CD20-positive B cell lines induced significant CD137 upregulation on NK cells ( Figures 1A-B) . This enhanced expression of CD137 occurred with purified NK cells (Supplementary Figure 1A) as observed in PBMCs, and predominantly in the CD56 dim subset of NK cells ( Figure 1C ).
Anti-CD137 mAb increases rituximab-mediated NK cell degranulation and cytotoxicity
We next investigated whether anti-CD137 agonistic mAb could enhance rituximab-mediated NK cell function, specifically degranulation and cytotoxicity. We used rituximab together with CD20-positive lymphoma cell lines (Raji, Ramos, and DHL-4) to induce CD107a expression on NK cells as a marker of granule mobilization 34 . We found that rituximab-induced degranulation could be significantly enhanced by anti-CD137 mAb (Figures 2A-C) . 4B4-1, an agonistic, ligandblocking, IgG1 anti-CD137 mAb similarly enhanced degranulation, while no effect of BBK-2, an antagonistic, ligand-blocking, IgG1 anti-CD137 mAb, was observed (data not shown).
Interferon-γ was also increased by anti-CD137 mAb (Supplementary Figure 2A) . We then assessed the effect of anti-CD137 mAb on rituximab-induced ADCC. Because CD137 is not Figure   2C ).
Anti-CD137 mAb potentiates anti-lymphoma activity of anti-CD20 mAb in-vivo
To test whether treatment with anti-CD137 mAb would enhance the anti-lymphoma activity of anti-CD20 mAb in-vivo, we used a mouse lymphoma known to be responsive to a mouse antimouse CD20 mAb 12 . The mechanism of the anti-lymphoma effect in this system is known to be dependent on FcR expression. Therefore it provides an opportunity to test the additional benefit of anti-CD137 mAb in a therapeutic tumor model. C57BL/6 mice were inoculated with syngeneic BL3750 lymphoma tumor cells, subcutaneously.
Mice then received either Rat IgG control on day 3, anti-CD20 mAb on day 3, anti-CD137 mAb on day 4, or anti-CD20 mAb on day 3 and anti-CD137 mAb on day 4 post-tumor inoculation. In the combination antibody group, anti-CD137 mAb was administered 24 hours after anti-CD20 mAb to allow upregulation of CD137 expression. Although anti-CD20 and anti-CD137 mAbs both had anti-tumor activity when used as single agents, their combination significantly Figures 3A-B) . To determine activity against wellestablished tumors, therapy was delayed until day 8 resulting in decreased efficacy of both single agents and combination. Anti-CD20 and anti-CD137 mAbs as monotherapy on day 8 or day 9, respectively, minimally delayed tumor growth ( Figure 3C ). Anti-CD20 mAb on day 8 followed by anti-CD137 mAb on day 9 resulted in transient tumor regression in all mice and complete regression with prolonged survival among half of combination treated mice ( Figures   3C-D) . Combination therapy at later timepoints, initiation of treatment on day 12 or day 15, was more effective than either single agent treatment, however the efficacy of each therapy was further reduced (data not shown).
Anti-CD20 and anti-CD137 mAbs combination activity is enhanced by sequential administration
The combined antibody therapy was next tested with simultaneous administration of both antibodies on day 3 to assess if the in-vivo enhanced activity of anti-CD20 and anti-CD137 mAbs required anti-CD20 mAb activation of NK cells prior to anti-CD137 mAb treatment.
Synergistic anti-tumor activity was observed when anti-CD20 mAb was administered prior to anti-CD137 mAb (Figure 4) . Significantly improved anti-tumor activity was also observed at a delayed treatment time point (8 days after tumor inoculation) for large tumors when anti-CD20 mAb was administered 24 hours prior to anti-CD137 mAb (Figures 3C-D) .
Anti-lymphoma activity of combination therapy requires NK cells and macrophages
To further investigate the mechanism of action of anti-CD20 and anti-CD137 mAb combination therapy, we next determined whether anti-CD20 mAb was capable of inducing CD137 upregulation in-vivo, similar to what we had observed in-vitro. Lymphoma-bearing mice were treated on day 3 post-tumor inoculation with IgG control or anti-CD20 antibody. Peripheral blood and primary tumors were collected and cell subsets (NK cells, macrophages, and T cells) were analyzed for CD137 expression. Consistent with our previous in-vitro findings, we observed that NK cells upregulated CD137 on their surface after in-vivo exposure to anti-CD20 mAb ( Figures   5A-B) . In-vitro culture of purified murine NK cells with BL3750 tumor at a 1:1 ratio, similarly resulted in increased NK cell CD137 expression with the addition of anti-CD20 mAb after 24 hours (7.9% to 73.5%, p<.001). Relative to circulating monocytes, tumor-infiltrating macrophages expressed high levels of CD137 which non-significantly increased following anti-CD20 mAb administration. CD4 T cells and CD8 T cells did not increase expression of CD137 in response to anti-CD20 mAb at the same time points. To confirm the role of NK cells and For personal use only. on November 12, 2017. by guest www.bloodjournal.org From macrophages in the therapeutic effect, we next performed a depletion experiment. We found that NK cell and macrophage depletion, and not CD8 T cell depletion, abrogated the therapeutic efficacy of anti-CD20 and anti-CD137 combination therapy (Figures 5C-D) . Three of ten mice depleted of CD8 T cells experienced late, >40 days post tumor-inoculation, relapses ( Figures   5C-D) .
Anti-CD137 mAb potentiates rituximab activity in a disseminated human lymphoma xenotransplant model
To confirm that the innate immune system is sufficient in mediating the anti-lymphoma activity of human anti-CD20 (rituximab) and anti-CD137 combination therapy in-vivo, we used a SCID mouse, human lymphoma xenotransplant model. SCID mice lack B and T cells but maintain a competent NK and macrophage cell population allowing us to determine if these cell populations mediate the therapeutic effect. SCID mice were inoculated intravenously through the retroorbital sinus with luciferase-labeled Raji cells. Mice then received either rat IgG control on day 3, rituximab on day 3, anti-CD137 mAb on day 4, or rituximab on day 3 and anti-CD137 mAb on day 4 post-tumor inoculation and this treatment was repeated weekly for 4 weeks. A five-fold increase in the percentage of peripheral blood NK cells expressing CD137 was observed 24 hours following rituximab treatment (data not shown). Combination of anti-CD137 agonistic mAb with rituximab significantly improved the rate of tumor regression and survival over rituximab alone ( Figure 6 ).
Rituximab-coated, autologous lymphoma cells induce CD137 upregulation on NK cells from human patients with B cell malignancies
We identified patients with B cell lymphomas who had circulating tumor cells (CTC). To mimic the in-vivo interaction between NK cells and tumor cells in the presence of rituximab, we incubated patient peripheral blood mononuclear cells that contained variable numbers of CTCs for 24 hours in-vitro either with rituximab or with trastuzumab. As we had observed using NK cells from healthy subjects, CD137 expression remained negative in the absence of mAb or in the presence of trastuzumab. In contrast, the inclusion of rituximab induced significant upregulation of CD137 with a concomitant decrease in CD16 expression ( Figure 7A ). Similar results were observed across 25 patient samples with a variety of histologies ( Figure 7B ).
Degree of CD137 upregulation correlated with percent CTC among follicular, diffuse large B cell, marginal zone, chronic lymphocytic, and CD20 + acute lymphoblastic leukemias and lymphomas ( Figure 7C ). This trend was not observed among cases of mantle cell histology.
Discussion
Since the approval and widespread adoption of rituximab for the treatment of lymphoma, many attempts have been made to enhance rituximab's efficacy 5 . Among these, strategies to enhance rituximab-mediated ADCC are particularly appealing. To date, most of these approaches have focused on the mAb itself by molecular engineering the biochemical structure to enhance the Fc-FcγR interaction 5 . In this study, we develop an alternative approach to enhancing rituximab's efficacy by stimulating effector NK cells implicated in tumor cell killing through ADCC.
We demonstrated that recognition of rituximab-coated tumor B cells induces upregulation of Following CD137 upregulation on NK cells, we showed that stimulation of this target with an agonistic mAb enhanced NK cell activity, as measured by granule mobilization and killing of rituximab-coated tumor cells, ADCC. In-vitro ADCC was assessed by chromium release assays in which relatively high ratios of CD137-expressing, pre-activated effector to target ratios were required. This may be due to decreased NK cell fitness resulting from the additional time in culture for pre-activation without exogenous cytokines 16 . However, by using purified and preactivated NK cells in-vitro, the predominant mechanism of anti-tumor activity is limited to ADCC. spontaneous cytotoxicity against CD137 ligand expressing AML posited to result from inhibitory, reverse signaling through the CD137 receptor on the NK cell following interaction with CD137
ligand. As spontaneous cytotoxicity and ADCC are independent mechanisms of NK cell cytotoxicity, our observations cannot be directly compared to the findings of Baessler.
To explore in-vivo activity and specifically the capacity of anti-CD137 mAb therapy to potentiate the anti-lymphoma activity of anti-CD20 mAb, we first used an immunocompetent syngeneic mouse lymphoma model selected as it is the only available model to test syngeneic anti-CD20 mAbs. Consistent with our human in-vitro data, we show that, although resting NK cells do not express CD137, in-vivo administration of anti-CD20 mAb in mice upregulates CD137 on the surface of NK cells. This might explain why anti-CD20 mAb needs to be administered prior to anti-CD137 mAb in order to see optimal therapeutic benefit. Though circulating monocyte expression of CD137 did not increase following anti-CD20 mAb treatment, the majority of intratumoral macrophages expressed CD137. In addition to being required for the efficacy of anti-CD20 mAb 12 , monocytes/macrophages may also participate in the additional benefit of anti- In conclusion, the results of our study suggest an innovative strategy to enhance rituximab's efficacy based on a sequential approach targeting both the tumor and the immune system. Rituximab, given first, induces upregulation of CD137 on NK cells involved in ADCC.
Subsequently, an agonistic anti-CD137 mAb is administered to enhance NK cell killing of rituximab-coated tumor cells. Therefore, NK cells stimulated by rituximab-bound tumor cells and consequently involved in rituximab-induced ADCC, will be targeted by the immunostimulatory mAb. This strategy is in contrast to approaches designed to stimulate NK cells non-specifically such as IL-2 42, 43 , IL-12 44 , or blocking antibodies against constitutively expressed inhibitory receptors such as anti-KIR mAbs 45 . These strategies result in dose-limiting toxicity due to systemic stimulation of NK cells. The combination of rituximab and anti-CD137 mAb should be well-tolerated in comparison to currently approved NK cell agonists, such as IL-2, or to conventional, cytotoxic chemotherapy.
Despite the focus of our work to ADCC, the effects of anti-CD137 mAb on non-NK cells will be important in the clinical development of anti-CD137 mAb therapy in B cell malignancies. 48, 49 and T cells including antigen-specific memory T cells 20, 29, 49 . In preclinical models, anti-CD137 mAb stimulation of this immune subset, specifically CD8 T cells, results in effective, anti-lymphoma, single agent therapy 23 suggesting that anti-CD137 mAb may be active as a monotherapy for B cell malignancies. This is consistent with our observation of anti-lymphoma activity limited to immunocompetent mice, and not observed in SCID mice, with anti-CD137 mAb monotherapy.
Stimulation of CD8 T cells appears also, however, to be responsible for the toxicity to hepatocytes observed in preclinical, mouse models 50 , and among 11% of patients with melanoma, renal cell, and ovarian tumors in a phase I trial of anti-CD137 mAb (BMS-663513) 51 .
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